Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance

With a growing population and rising rates of chronic conditions, the demand for better healthcare solutions has never been greater. Thus, scooping shares of fundamentally sound healthcare stocks, Pfizer Inc. , The Cigna Group and Centene Corporation . All three stocks offer an easier entry point, being undervalued and receiving high upside potential from analysts.

Chronic diseases are becoming more prevalent worldwide, leading to a surge in demand for innovative treatments. As conditions like heart disease, diabetes, and respiratory issues rise, healthcare providers and pharmaceutical companies must meet the increasing need for effective and accessible solutions to manage these ailments.

The induction of Artificial Intelligence (AI) and machine learning are reshaping the healthcare landscape. By improving task management, patient services, and complex measurements, AI is streamlining operations and facilitating the healthcare industry’s growth, making it more efficient and patient-centric.

Moreover, the industry continues to demonstrate its potential, as seen with the U.S. Food and Drug Administration’s approval of 43 new drugs for chronic conditions this year. With global pharmaceutical revenue expected to hit $1.45 trillion by 2029, growing at a steady CAGR of 4.7%, the future of healthcare looks promising.

With these conductive trends in mind, let us dive deep into the fundamentals of three healthcare stocks.

Pfizer Inc. (PFE)

PFE discovers, develops, manufactures, and markets pharmaceutical products. The company offers medicines and vaccines across therapeutic areas, including cardiovascular, infectious diseases, immunology, oncology, and women’s health.

On November 20, PFE announced the approval by the European Commission (EC) for HYMPAVZI™ for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A without FVIII inhibitors or severe hemophilia B without FIX inhibitors.

The approval strengthens PFE’s position in the genetic disease treatment market and facilitates stable growth prospects through its offerings.

On October 22, PFE announced the U.S. Food and Drug Administration’s (FDA) approval of ABRYSVO, its bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.

The approval broadens the company’s infectious disease treatment pipeline and helps solidify the company’s position as an industry leader.

PFE’s forward non-GAAP P/E of 8.96x is 57% lower than the industry average of 12.12x. Its forward EV/EBIT multiple of 10.35 is 39.3% lower than the sector average of 12.22x. Likewise, the stock’s forward Price/Book of 1.68x is 40% lower than the industry average of 2.80x.

For the fiscal 2024 third quarter that ended September 29, PFE’s total revenues increased 31.2% year-over-year to $17.70 billion. The company’s adjusted net income and adjusted earnings per common share attributable to PFE common shareholders stood at $6.05 billion and $1.06, compared to a net loss and loss per share of $968 million and $0.17 in the prior year’s quarter, respectively.

Analysts expect PFE’s revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 21.3% and 369.7% year-over-year to $17.28 billion and $0.47, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters.

Shares of PFE have surged 1.4% intraday, closing the last trading session at $26.20. Its 12-month price target of $31.93 reflects a 21.8% potential upside.

PFE’s POWR Ratings mirror its solid fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

PFE has an A grade for Growth and a B for Value. It is ranked #27 out of 154 stocks in the Medical - Pharmaceuticals industry.

In addition to the POWR Rating highlighted above, you can check PFE’s ratings for Stability, Sentiment, Momentum, and Quality here.

The Cigna Group (CI)

CI offers insurance and related services. It has two segments: Evernorth and Cigna Healthcare, which provide coordinated and point-solution health services, delivering medical, pharmacy, behavioral health, dental, and other products, including Medicare plans and international health coverage for individuals and employees.

On January 31, CI announced a definitive agreement for Health Care Service Corporation (HCSC) to acquire its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses for an approximate transaction value of $3.7 billion.

This agreement would enable CI to uphold value for its stakeholders by freeing up resources to accelerate investment in its services platform.

CI’s forward non-GAAP P/E of 11.85x is 43.2% lower than the industry average of 20.86x. The stock’s forward EV/Sales of 0.50x is 86.6% lower than the sector average of 3.73x. Additionally, its forward Price/Book multiple of 2.23 is 20.1% lower than the 2.80x industry average.

For the fiscal 2024 third quarter that ended September 30, CI’s adjusted revenues increased 29.8% year-over-year to $63.70 billion. Its adjusted income from operations rose 5% from the year-ago value to $2.11 billion. Moreover, the company’s adjusted income from operations per share grew 10.9% from the prior year’s quarter to $7.51.

The consensus revenue estimate of $63.03 billion for the fiscal fourth quarter (ending December 2024) reflects a year-over-year rise of 23.2%. Its EPS for the same period is expected to increase 15.2% from the prior year’s period to $7.82. Also, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.

CI’s shares have gained 25.5% over the past year, closing the last trading session at $337.80. Wall Street analysts expect the stock to reach $397.38 in the near term, indicating a potential upside of 17.6%.

CI’s POWR Ratings reflect its sound outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.

CI has a B grade for Growth and Value. It is ranked #2 within the 10-stock A-rated Medical - Health Insurance industry.

To check CI’s Quality, Momentum, Sentiment, and Stability ratings, click here.

Centene Corporation (CNC)

CNC provides essential healthcare programs and services to underinsured and uninsured families, commercial organizations, and military families. The company operates through Medicaid; Medicare; Commercial; and Other segments.

On May 2, CNC’s Medicare business, Wellcare, announced a partnership with Wellvana to expand affordable, patient-centered primary healthcare for Medicare Advantage members in Georgia, Tennessee, and Texas.

This partnership supports independent primary care physicians, improves clinical outcomes, and strengthens CNC’s presence in value-based care, driving growth in its Medicare sector.

CNC’s forward non-GAAP P/E of 8.79x is 57.9% lower than the industry average of 20.86x. Its forward Price/Book of 1.18x is 58% lower than the sector average of 2.80x. Furthermore, the stock’s forward EV/EBITDA of 7.89x is 42% lower than the 13.60x industry average.

For the fiscal third quarter that ended September 30, 2024, CNC’s total revenues increased 10.5% year-over-year to $42.02 billion. The net earnings and earnings per common share attributable to CNC grew 52% and 56.3% from the prior year’s quarter to $713 million and $1.36, respectively.

For the fiscal year ending December 2024, Street expects CNC’s revenue to increase 4.8% year-over-year to $161.37 billion. Its EPS for the same period is expected to rise 2.2% year-over-year from the prior year’s period to $6.83 Plus, the company has surpassed the consensus revenue and EPS estimates in all of its four trailing quarters.

Shares of CNC marginally surged intraday to close the last trading session at $60. Its 12-month price target of $80.83 reflects a 34.7% potential upside.

CNC’s POWR Ratings reflect its sound outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.

CNC has a B grade for Value and Growth. Out of 10 stocks in the Medical - Health Insurance industry, CNC is ranked #3.

To check CNC’s Quality, Momentum, Sentiment, and Stability ratings, click here.

What To Do Next?

Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today’s volatile markets:

3 Stocks to DOUBLE This Year >

PFE shares were trading at $25.82 per share on Monday afternoon, down $0.39 (-1.49%). Year-to-date, PFE has declined -3.48%, versus a 28.12% rise in the benchmark S&P 500 index during the same period.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores?

The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value Score

For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth Score

Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum Score

Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM Score

If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank

A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Pfizer (PFE)

New York-based Pfizer markets a wide range of drugs and vaccines. Pfizer’s Biopharma reporting segment includes three broad therapeutic areas, Primary Care (Internal Medicine, Vaccines, Migraine and COVID-19 products), Specialty Care (Inflammation & Immunology, Rare Disease and Hospital [excluding Paxlovid]) and Oncology.

PFE is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9; value investors should take notice.

For fiscal 2024, 10 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.29 to $2.91 per share. PFE boasts an average earnings surprise of 74.5%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, PFE should be on investors' short list.

Zacks Investment Research

The price-to-book (P/B) ratio is widely favored by value investors for identifying low-priced stocks with exceptional returns. The ratio is used to compare a stock’s market value/price to its book value.

The P/B ratio is calculated as below:

P/B ratio = market price per share/book value of equity per share

The P/B ratio reflects how many times book value investors are ready to pay for a share. So, if the share price is $10 and the book value of equity is $5, investors are ready to pay two times the book value. Ideally, a P/B value under 1.0 is considered good, indicating a potentially undervalued stock. However, value investors often consider stocks with a P/B value under 3.0.

The P/B ratio helps to identify low-priced stocks with high growth prospects. Pfizer PFE, General Motors Company GM, Select Medical SEM, AXIS Capital Holdings Limited AXS and ZIM Integrated Shipping Services ZIM are some such stocks.

Now, let us understand the concept of book value.

What is Book Value?

There are several ways by which book value can be defined. Book value is the total value that would be left over, according to the company’s balance sheet, if it goes bankrupt immediately. In other words, this is what shareholders would theoretically receive if a company liquidates all its assets after paying off all its liabilities.

It is calculated by subtracting total liabilities from the total assets of a company. In most cases, this equates to common stockholders’ equity on the balance sheet. However, depending on the company’s balance sheet, intangible assets should also be subtracted from the total assets to determine book value.

Understanding P/B Ratio

By comparing the book value of equity to its market price, we get an idea of whether a company is under or overpriced. However, like P/E or P/S ratio, it is always better to compare P/B ratios within industries.

A P/B ratio of less than one means that the stock is trading at less than its book value or the stock is undervalued and, therefore, a good buy. Conversely, a stock with a ratio greater than one can be interpreted as being overvalued or relatively expensive.

For example, a stock with a P/B ratio of 2 means that we pay $2 for every $1 of book value. Thus, the higher the P/B, the more expensive the stock.

But there is a warning. A P/B ratio of less than one can also mean that the company is earning weak or even negative returns on its assets or that the assets are overstated, in which case the stock should be shunned because it may be destroying shareholder value. Conversely, the stock’s price may be significantly high — thereby pushing the P/B ratio to more than one — in the likely case that it has become a takeover target, a good enough reason to own the stock.

Moreover, the P/B ratio is not without limitations. It is useful for businesses like finance, investments, insurance and banking or manufacturing companies with many liquid/tangible assets on the books. However, it can be misleading for firms with significant R&D expenditure, high debt, service companies, or those with negative earnings.

In any case, the ratio is not particularly relevant as a standalone number. One should analyze other ratios like P/E, P/S and debt to equity before arriving at a reasonable investment decision.

Screening Parameters

Price to Book (common Equity) less than X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.

Price to Sales less than X-Industry Median:The P/S ratio determines how much the market values every dollar of the company’s sales/revenues — a lower ratio than the industry makes the stock attractive.

Price to Earnings using F(1) estimate less than X-Industry Median: The P/E ratio (F1) values a company based on its current share price relative to its estimated earnings per share — a lower ratio than the industry is considered better.

PEG less than 1: PEG links the P/E ratio to the future growth rate of the company. The PEG ratio portrays a more complete picture than the P/E ratio. A value of less than 1 indicates that the stock is undervalued, and investors need to pay less for a stock that has bright earnings growth prospects.

Current Price greater than or equal to $5: They must all be trading at a minimum of $5 or higher.

Average 20-Day Volume greater than or equal to 100,000: A substantial trading volume ensures that the stock is easily tradable.

Zacks Rank less than or equal to #2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.

Value Score equal to A or B: Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best opportunities in the value investing space.

5 Low Price-to-Book Stocks

Here are five of the nine stocks that qualified the screening: 

New York-based Pfizer is one of the largest drugmakers in the world, marketing a wide range of drugs and vaccines. Pfizer currently has a Zacks Rank #2 and a Value Score of A. You can see the complete list of today’s Zacks #1 Rank stocks here.

PFE has a projected 3-5-year EPS growth rate of 12.5%.

Headquartered in Detroit, General Motors is one of the world’s largest automakers. General Motors, along with its strategic partners, produces, sells and services cars, trucks and parts under four core brands — Chevrolet, Buick, GMC and Cadillac. General Motors assembles passenger cars, crossover vehicles, light trucks, sport utility vehicles, vans and other vehicles. GM has a projected 3-5-year EPS growth rate of 12.8%.

General Motors currently has a Zacks Rank #2 and a Value Score of A.

Mechanicsburg, PA-based Select Medical is a healthcare company, which owns long-term acute care and inpatient rehabilitation hospitals, as well as occupational health and physical therapy clinics.

Select Medical has a Zacks Rank #2 and a Value Score of A at present. SEM has a projected 3-5-year EPS growth rate of 10.4%.

AXIS Capital Holdings Limited is the Bermuda-based holding company for the AXIS group of companies. The company provides a broad range of specialty insurance and reinsurance solutions to its clients on a worldwide basis, through operating subsidiaries and branch networks based in Bermuda, the United States, Europe, Singapore, Canada, Latin America and the Middle East. The company also maintains marketing offices in Brazil, France and Spain. Its business consists of two distinct global underwriting platforms, AXIS Insurance and AXIS Re.

AXIS Capital presently has a Zacks Rank #2 and a Value Score of A. The company has a projected 3-5-year EPS growth rate of 27.3%.

ZIM Integrated Shipping Services provides container shipping and related services, along with its subsidiaries. The company offers dry, reefer, project, out-of-gauge, breakbulk and dangerous cargo services and inland transport services. ZIM Integrated Shipping Services Ltd. is based in Haifa, Israel.

ZIM Integrated Shipping Services has a Zacks Rank #1 and a Value Score of A. ZIM has a projected 3-5-year EPS growth rate of 28.4%.

Get the remaining stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back-testing software.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance

Zacks Investment Research

Key Takeaways

• Tyson Foods, AXIS Capital, Pfizer and General Motors stocks boast a low price to cash flow ratio (P/CF).
• P/CF ratio evaluates the market price of a stock relative to the amount of cash flow on a per-share basis.
• Register now to see our 7 Best Stocks for the Next 30 Days report - free today!

The U.S. stock market retreated on Wednesday as investors booked profits and adopted a cautious approach after earlier gains in November. The pullback came as market participants evaluated fresh economic data and corporate earnings. Trading volumes were also lighter than usual ahead of the Thanksgiving holiday.

The S&P 500 dropped 0.38% to settle at 5,998.74, ending its seven-session winning streak. The Nasdaq Composite lost 0.6%, closing at 19,060.48, while the Dow Jones Industrial Average fell 138.25 points, or 0.31%, to 44,722.06.

Heading into December, investor focus is expected to shift toward year-end positioning and factors that might shape the Federal Reserve’s policy. In this environment, value stocks could draw attention as a compelling investment option. Often trading below their intrinsic value, they provide a margin of safety, which can be especially appealing amid market uncertainties.

When evaluating value stocks, one of the most effective valuation metrics is the Price to Cash Flow (P/CF) ratio. Companies like Tyson Foods, Inc. TSN, AXIS Capital Holdings Limited AXS, Pfizer Inc. PFE and General Motors Company GM boast a low P/CF ratio. The P/CF ratio evaluates the market price of a stock relative to the amount of cash flow that the company is generating on a per-share basis — the lower the number, the better.

Price to Cash Flow Reflects Financial Health

You must be wondering why we consider the P/CF valuation metric when the most widely used valuation metric is Price/Earnings (or P/E). An important factor that makes P/CF a highly dependable metric is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, truly diagnosing a company’s financial health.

Analysts caution that a company’s earnings are subject to accounting estimates and management manipulation. Then again, cash flow is quite reliable. Net cash flow unveils how much money a company generates and how effectively management is deploying the same.

A positive cash flow indicates an increase in the company’s liquid assets. This gives the company the means to settle debt, meet its expenses, reinvest in the business, endure downturns and finally undertake shareholder-friendly moves. Negative cash flow implies a decline in the company’s liquidity, which, in turn, lowers its flexibility to support these endeavors.

What’s the Best Value Investing Strategy?

An investment decision based solely on the P/CF metric may not yield the desired results. To identify stocks that are trading at a discount, you should expand your search criteria and also consider the price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of A or B to your search criteria should lead to even better results as these eliminate the chance of falling into a value trap.

Here are the parameters for selecting true-value stocks: 

P/CF less than or equal to X-Industry Median.

Price greater than or equal to 5: The stocks must all be trading at a minimum of $5 or higher.

Average 20-Day Volume greater than 100,000: A substantial trading volume ensures that the stock is easily tradable.

P/E using (F1) less than or equal to X-Industry Median: This parameter shortlists stocks that are trading at a discount or are equal to their peers.

P/B less than or equal to X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.

P/S less than or equal to X-Industry Median: The P/S ratio determines how a stock price compares to the company’s sales — the lower the ratio, the more attractive the stock is.

PEG less than 1: The ratio is used to determine a stock's value by taking the company's earnings growth into account. The PEG ratio gives a more complete picture than the P/E ratio. A value of less than 1 indicates that the stock is undervalued and that investors need to pay less for a stock that has robust earnings growth prospects.

Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.

Value Score of less than or equal to B: Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank #1 or 2 offer the best upside potential.

Here are four of the 12 value stocks that qualified the screening:

Tyson Foods, one of the world’s largest food companies and a recognized leader in protein, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 57%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Tyson Foods’ current financial year sales and earnings per share (EPS) suggests growth of 2% and 12.9%, respectively, from the year-ago period. TSN has a Value Score of A. Shares of TSN have surged 37.6% in the past year.

AXIS Capital Holdings, a global specialty underwriter and provider of insurance and reinsurance solutions, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 90.3%, on average.

The Zacks Consensus Estimate for AXIS Capital’s current financial year sales and EPS suggests growth of 7.4% and 10.6%, respectively, from the year-ago period. AXS has a Value Score of A. The stock has advanced 65.5% in the past year.

See the Zacks Earnings Calendar to stay ahead of market-making news.

Pfizer, which develops, manufactures, markets, distributes, and sells biopharmaceutical products, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 74.5%, on average.

The Zacks Consensus Estimate for Pfizer’s current financial year sales and EPS suggests growth of 8.3% and 58.2%, respectively, from the year-ago period. Pfizer has a Value Score of A. Shares of PFE have declined 15.2% in the past year.

General Motors, which designs, builds, and sells cars, trucks, crossovers, and automobile parts globally, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 17.5%, on average.

The Zacks Consensus Estimate for General Motors’ current financial year sales and EPS suggests growth of 4.8% and 34.8%, respectively, from the year-ago period. General Motors has a Value Score of A. Shares of GM have rallied 75.6% in the past year.

You can get the rest of the stock on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and backtest them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.

Zacks Investment Research